A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL

NCT01874288 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
24
Enrollment
INDUSTRY
Sponsor class

Stopped Clinical benefit was noted in the earlier portion of the trial; hence, participants were not enrolled in 2 expansion cohorts and the study was terminated early.

Conditions

Interventions

Sponsor

Alopexx Oncology, LLC